-
21.发明申请公开(公告)号：US20250011784A1
公开(公告)日：2025-01-09
申请号：US18752689
申请日：2024-06-24
Applicant: VICO Therapeutics B.V.
IPC: C12N15/113 , A61P25/28
Abstract: The current invention provides an improved oligonucleotide and its use for treating, ameliorating, preventing, delaying and/or treating a human cis-clement repeat instability associated genetic neuromuscular or neurodegenerative disorder.
-
公开(公告)号：US12187813B2
公开(公告)日：2025-01-07
申请号：US18167350
申请日：2023-02-10
Applicant: Florida Atlantic University Board of Trustees , University of Florida Research Foundation
Inventor： Predrag Cudic , Jay McLaughlin
IPC: A61K31/4045 , A61K9/00 , A61K47/64 , A61K47/65 , A61P25/04 , A61P25/06 , A61P25/16 , A61P25/18 , A61P25/28 , A61P25/36 , C07K5/12 , C07K7/64 , A61K38/00 , C40B40/10
Abstract: Novel cyclic peptides, cyclic peptide conjugates and compositions containing them for treating neurological diseases in a subject include an Odorranalectin (OL) sequence or modified OL sequence as a scaffold and a biologically active peptide or protein and/or therapeutic agent conjugated thereto. Methods of treatment of neurological diseases are based on intranasal delivery of a cyclic peptide or cyclic peptide conjugate as described herein. Combinatorial libraries that include a plurality of cyclic peptides have also been developed and can be used to screen for a ligand(s) for a receptor of interest.
-
公开(公告)号：US12186379B2
公开(公告)日：2025-01-07
申请号：US17447607
申请日：2021-09-14
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： Sangkon Oh , Gerard Zurawski
Abstract: Methods and compositions for treating multiple sclerosis using dendritic cell anti-ASGPR antibodies fused to myelin basic protein or myelin oligodendrocyte glycoprotein are provided.
-
24.发明申请
公开(公告)号：US20250002503A1
公开(公告)日：2025-01-02
申请号：US18692906
申请日：2022-09-16
Applicant: ESTEVE PHARMACEUTICALS, S.A.
Inventor： José-Miguel VELA-HERNÁNDEZ , Manuel MERLOS-ROCA , Xavier NAVARRO-ACEBES , Mireia HERRANDO-GRABULOSA
IPC: C07D498/10 , A61K31/5386 , A61P21/00 , A61P25/28
Abstract: The present invention relates to compounds having pharmacological activity towards the sigma (#) receptor, and more particularly to oxadiazaspiro compounds having this pharmacological activity, for use in neuroprotection or in the treatment of motoneuron degeneration.
-
公开(公告)号：US20250000945A1
公开(公告)日：2025-01-02
申请号：US18690533
申请日：2022-09-13
Applicant: The Regents of the University of California
Inventor： Denise Montell , Xiaoran (Sharon) Guo , Diego Acosta Alvear
Abstract: Methods and compositions are provided for enhancing endoplasmic reticulum-associated degradation (ERAD) and suppressing pathological accumulation of misfolded proteins in cells by increasing expression or activity of zinc transporter protein 7 (ZIP7). Methods of treating a subject for a disorder associated with protein misfolding are also provided, including methods of gene therapy for expressing ZIP7 in vivo in effective amounts sufficient to suppress pathological accumulation of misfolded proteins.
-
公开(公告)号：US20250000917A1
公开(公告)日：2025-01-02
申请号：US18700380
申请日：2022-10-21
Applicant: MORINAGA MILK INDUSTRY CO., LTD.
Inventor： Daisuke Asaoka , Toshifumi Okusa , Nobuhiro Sato , Kazuya Ono , Kanetada Shimizu , Noriko Katsumata
IPC: A61K35/745 , A61P25/28
Abstract: The brain atrophy suppressor contains, as an active ingredient, a culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) for administration to a subject selected from a healthy individual, an individual diagnosed with mild cognitive impairment, an individual assessed as having cognitive decline and a subject at a risk of a neurodegenerative disease.
-
公开(公告)号：US12180205B2
公开(公告)日：2024-12-31
申请号：US17276502
申请日：2019-09-18
Applicant: BIOGEN MA INC.
Inventor： Nathan Genung , Kevin M. Guckian , Jeffrey Vessels , Lei Zhang , Ryan Gianatassio , Edward Yin Shiang Lin , Zhili Xin
IPC: C07D417/14 , A61P25/28 , C07D417/06
Abstract: Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.
-
公开(公告)号：US12178838B2
公开(公告)日：2024-12-31
申请号：US17437331
申请日：2020-03-13
Applicant: Lactocore, Inc.
Inventor： Anton Malyshev , Igor Doronin , Gennady Babkin , Askar Kuchumov
Abstract: A pharmaceutical composition comprising a synthetic neuromodulatory peptide is described. The invention discloses neuromodulatory peptides as defined in the claims and methods of using such molecules for therapeutic application. The neuromodulatory peptides included in the composition have been found to be effective in treatment of depression and other mood disorders, including anxiety.
-
公开(公告)号：US20240425591A1
公开(公告)日：2024-12-26
申请号：US18700972
申请日：2022-10-14
Inventor： Howard L. WEINER , Tanuja CHITNIS , Tarun SINGHAL , Kunwar SHAILUBHAI
Abstract: The present disclosure provides methods of suppressing the activation of microglial cells, methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of ameliorating or treating specific diseases that affect the CNS by nasally administering an anti-CD3 antibody.
-
公开(公告)号：US20240424142A1
公开(公告)日：2024-12-26
申请号：US18689161
申请日：2022-09-07
Applicant: Yale University
Inventor： Jaime GRUTZENDLER , Peng YUAN , Mengyang ZHANG , Lei TONG
Abstract: Described herein is a method of reversing or preventing a formation or enlargement of an axonal spheroid. The method includes introducing into a neuron affected by formation or enlargement of the axonal spheroid a compound that downregulates PLD3 expression level or activity. Also described herein is a method of treating or preventing a neurodegenerative condition in a subject in need thereof. The method includes administering to the subject a compound that downregulates PLD3 expression level or activity in a neuron cell affected by the neurodegenerative condition. Further described herein is a pharmaceutical composition for treating a neurodegenerative condition in a subject. The pharmaceutical composition includes a compound that downregulates PDL3 expression level or activity in a neuron cell affected by the neurodegenerative condition; and a pharmaceutically acceptable carrier.
